{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T13:04:56Z","timestamp":1777727096305,"version":"3.51.4"},"reference-count":27,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Int Med Res"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:p>Patients with multiple sclerosis (MS) repeatedly receive therapies that cause B-lymphocyte depletion. This may lead to abnormal immune responses following coronavirus disease 2019 (COVID-19) vaccination, as has been suggested previously. We therefore evaluated post-vaccination immune responses in a patient with MS treated with ocrelizumab. The intervals between ocrelizumab infusions and vaccination were as recommended by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society. A reactive immune response was observed in this patient following vaccination. This suggests that appropriate intervals between ocrelizumab infusions and COVID-19 vaccinations may permit the generation of efficacious immune responses in patients receiving B-lymphocyte depleting therapies.<\/jats:p>","DOI":"10.1177\/03000605211044378","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T05:06:51Z","timestamp":1631768811000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Anti-severe acute respiratory syndrome coronavirus-2 antibody responses following Pfizer-BioNTech vaccination in a patient with multiple sclerosis treated with ocrelizumab: a case report"],"prefix":"10.1177","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1610-036X","authenticated-orcid":false,"given":"Hubert","family":"Mado","sequence":"first","affiliation":[{"name":"Department of Neurology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Kubicka-B\u0105czyk","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Adamczyk-Sowa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"bibr1-03000605211044378","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101416"},{"key":"bibr2-03000605211044378","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13495"},{"key":"bibr3-03000605211044378","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000498"},{"key":"bibr4-03000605211044378","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2020.106451"},{"key":"bibr5-03000605211044378","first-page":"1","volume":"27","author":"Khayat-Khoei M","year":"2021","journal-title":"J Neurol"},{"key":"bibr6-03000605211044378","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102323"},{"key":"bibr7-03000605211044378","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102315"},{"key":"bibr8-03000605211044378","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102341"},{"key":"bibr9-03000605211044378","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13517"},{"key":"bibr10-03000605211044378","doi-asserted-by":"crossref","unstructured":"Mado H, Adamczyk-Sowa M. Comment on the paper\n                      Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab\n                      : The likely explanation for this phenomenon based on our observations.\n                      J Neurol\n                      . 2021; 1\u20132. Available from: https:\/\/link.springer.com\/10.1007\/s00415-021-10547-0","DOI":"10.1007\/s00415-021-10547-0"},{"key":"bibr11-03000605211044378","doi-asserted-by":"publisher","DOI":"10.1111\/head.12246"},{"key":"bibr12-03000605211044378","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2"},{"key":"bibr13-03000605211044378","doi-asserted-by":"publisher","DOI":"10.5603\/PJNNS.a2021.0016"},{"key":"bibr14-03000605211044378","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1250881"},{"key":"bibr15-03000605211044378","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a032037"},{"key":"bibr16-03000605211044378","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.3365"},{"key":"bibr17-03000605211044378","doi-asserted-by":"publisher","DOI":"10.1007\/s00115-020-00937-6"},{"key":"bibr18-03000605211044378","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010380"},{"key":"bibr19-03000605211044378","unstructured":"European Medicines Agency. Ocrevus European public assessment report: Product information, annex I, summary of product characteristics, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ocrevus-epar-product-information_en.pdf (2018, accessed 5 March 2021)."},{"key":"bibr20-03000605211044378","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102195"},{"key":"bibr21-03000605211044378","unstructured":"Narodowy Instytut Zdrowia Publicznego PZH \u2013 Pa\u0144stwowy Instytut Badawczy. Czy nale\u017cy wykonywa\u0107 test serologiczny w celu sprawdzenia odpowiedzi immunologicznej po szczepieniu przeciw COVID-19? https:\/\/szczepienia.pzh.gov.pl\/faq\/czy-nalezy-wykonywac-test-serologiczny-w-celu-sprawdzenia-odpowiedzi-immunologicznej-po-szczepieniu-przeciw-covid-19 (2021, accessed 16 July 2021)."},{"key":"bibr22-03000605211044378","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102983"},{"key":"bibr23-03000605211044378","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211012835"},{"key":"bibr24-03000605211044378","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05397-7"},{"key":"bibr25-03000605211044378","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkab038"},{"key":"bibr26-03000605211044378","first-page":"1","author":"Etemadifar M","year":"2021","journal-title":"Hum Vaccin Immunother."},{"key":"bibr27-03000605211044378","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577599"}],"container-title":["Journal of International Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03000605211044378","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03000605211044378","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03000605211044378","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:48:36Z","timestamp":1777459716000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03000605211044378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1177\/03000605211044378"],"URL":"https:\/\/doi.org\/10.1177\/03000605211044378","relation":{},"ISSN":["0300-0605","1473-2300"],"issn-type":[{"value":"0300-0605","type":"print"},{"value":"1473-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9]]},"article-number":"03000605211044378"}}